Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 169

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Benzodiazepines for schizophrenia

Open access
Dold, Markus, Li, Chunbo, Tardy, Magdolna, Khorsand, Vesal, Gillies, Donna, Leucht, Stefan · 2012 · Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Because of the high number of people with schizophrenia not responding adequately to monotherapy with antipsychotic agents, the evidence regarding the efficacy and safety of additional medication was examined in a number of clinical trials. One approach to this research question was the use of benzodiazepines, as monotherapy as well as in combination with antipsychotics. OBJECTIVES: To determine the efficacy, acceptability, and tolerability of benzodiazepines in people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: In February 2011, we updated the literature search of the previous version of this systematic review (last search March 2005). We searched the trial register of the Cochrane Schizophrenia Group (containing methodical searches of BIOSIS, CINAHL, Dissertation abstracts, EMBASE, LILACS, MEDLINE, PSYNDEX, PsycINFO, RUSSMED, Sociofile, supplemented with hand searching of relevant journals and numerous conference proceedings). Additionally, we inspected references of all identified studies for further relevant studies and contacted authors of relevant publications in order to obtain missing data from existing trials. We applied no language restrictions. SELECTION CRITERIA: We included all randomised controlled trials comparing benzodiazepines (as monotherapy or as adjunctive agent) with antipsychotic drugs or placebo for the pharmacological management of schizophrenia and/or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: Review authors (MD and CL) analysed independently the new references of the update-search referring to the inclusion criteria. MD and CL extracted all data from the included trials. For dichotomous outcomes we calculated risk ratios (RR) and their 95% confidence intervals (CI). We analysed continuous data by using mean differences (MD) and their 95% CI. We assessed each pre-selected outcome from the included trials with the risk of bias tool. MAIN RESULTS: The 2011 update search yielded three further randomised controlled trials. The review currently includes 34 studies with 2657 participants. Most studies were characterised by a small sample size, short duration, and incomplete outcome data reporting.Benzodiazepine monotherapy is compared with placebo in eight trials. The proportion of participants with no clinically important response did not significantly differ between those given benzodiazepines or placebo (N = 382, 6 RCTs, RR 0.67 CI 0.44 to 1.02). The results from the various rating scales applied to assess global and mental state were inconsistent.Fourteen studies examined benzodiazepine monotherapy in comparison with antipsychotic monotherapy. Clinically important treatment response assessment revealed no statistically significant difference between the study groups (30 minutes: N = 44, 1 RCT, RR 0.91 CI 0.58 to 1.43; 60 minutes: N = 44,1 RCT, RR 0.61 CI 0.20 to 1.86; 12 hours: N = 66, 1 RCT, RR 0.75 CI 0.44 to 1.30; pooled short-term studies: N = 112, 2 RCTs, RR 1.48 CI 0.64 to 3.46). Desired sedation occurred significantly more often among participants in the benzodiazepine group than in the antipsychotic group at 20 and 40 minutes. No significant between-group differences could be identified for global and mental state or occurrence of adverse effects.Twenty trials compared benzodiazepine augmentation of antipsychotics with antipsychotic monotherapy. Referring to clinically important response, statistically significant improvement could be demonstrated only for the first 30 minutes of augmentation treatment (30 minutes: 1 RCT, N = 45, RR 0.38 CI 0.18 to 0.80; 60 minutes: N = 45,1 RCT, RR 0.07 CI 0.00 to 1.13; 12 hour: N = 67,1 RCT, RR 0.85 CI 0.51 to 1.41; pooled short-term studies: N = 511, 6 RCTs, RR 0.87 CI 0.49 to 1.54). Analyses of the global and mental state yielded no between-group differences except for desired sedation at 30 as well as 60 minutes (30 minutes: N = 45, 1 RCT, RR 2.25 CI 1.18 to 4.30; 60 minutes: N = 45, 1 RCT, RR 1.39 CI 1.06 to 1.83). AUTHORS' CONCLUSIONS: There is currently no convincing evidence to confirm or refute the practise of administering benzodiazepines as monotherapy or in combination with antipsychotics for the pharmacological treatment of schizophrenia and schizophrenia-like psychosis. Low-quality evidence suggests that benzodiazepines are effective for very short-term sedation and could be considered for calming acutely agitated people with schizophrenia. Measured by the overall attrition rate, the acceptability of benzodiazepine treatment appears to be adequate. Adverse effects were generally poorly reported. High-quality future research projects with large sample sizes are required to clarify the evidence of benzodiazepine treatment in schizophrenia, especially regarding long-term augmentation strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd006391.pub2

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 149

  1. Azima, 1962, The effects of chlordiazepoxide (librium) in anxiety states: A multi-blind study, Canadian Psychiatric Journal, 7, 44
  2. Barbee, 1992, Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia [published erratum appears in American Journal of Psychiatry 1992 ;149:1129] [see comments], American Journal of Psychiatry, 149, 506, 10.1176/ajp.149.4.506 · DOI
  3. Battaglia, 1997, Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study, American Journal of Emergency Medicine, 15, 335, 10.1016/S0735-6757(97)90119-4 · DOI · Paper page
  4. Carpenter, 1999, Diazepam treatment of early signs of exacerbation in schizophrenia, American Journal of Psychiatry, 156, 299, 10.1176/ajp.156.2.299 · DOI
  5. Cheung, 1981, Schizophrenics fully remitted on neuroleptics for 3-5 years-To stop or continue drugs?, British Journal of Psychiatry, 138, 490, 10.1192/bjp.138.6.490 · DOI
  6. Chouinard, 1993, A double-blind randomized clinical trial of rapid tranquilization with i.m. clonazepam and i.m. haloperidol in agitated psychotic patients with manic symptoms, Canadian Journal of Psychiatry, 38, 114
  7. Dorevitch, 1997, Treatment of long-term tardive dyskinesia with Vitamin E, Biological Psychiatry, 41, 114, 10.1016/S0006-3223(96)00367-8 · DOI
  8. Dorevith, 1999, Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior, American Journal of Psychiatry, 156, 142, 10.1176/ajp.156.1.142 · DOI
  9. Foster, 1997, Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting, International Clinical Psychopharmacology, 12, 175, 10.1097/00004850-199705000-00009 · DOI
  10. Garza-Trevino, 1989, Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation, American Journal of Psychiatry, 146, 1598, 10.1176/ajp.146.12.1598 · DOI
  11. Gundlach, 1966, A Double-blind outpatient study of diazepam (Valium) and placebo, Psychopharmacologia, 9, 81, 10.1007/BF00404713 · doi:10.1007/bf00404713
  12. Guz, 1988, Lorazepam and haloperidol in the treatment of schizophrenic patients, Jornal Brasileiro de Psiquiatria, 37, 205
  13. Guz, 1972, The therapeutic effects of lorazepam in psychotic patients treated with haloperidol - A double blind study, Current Therapeutic Research, 14, 767
  14. Hankoff, 1962, A reference study of ataraxics. A two-week double blind outpatient evaluation, The Journal of New Drugs, 179, 173, 10.1177/009127006200200305 · doi:10.1177/009127006200200305
  15. Hanlon, 1969, Combined drug treatment of newly hospitalized, acutely ill psychiatric patients, Diseases of the Nervous System, 30, 104
  16. Hanlon, 1970, Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine, Diseases of the Nervous System, 31, 171
  17. Hanlon, 1975, Effects od control techniques on therapeutic outcome in a controlled trial, International Pharmacopsychiatry, 10, 169, 10.1159/000468187 · doi:10.1159/000468187
  18. Holden, 1970, Weight changes with schizophrenic psychosis and psychotropic drug therapy, Psychosomatics, 11, 551, 10.1016/S0033-3182(70)71576-4 · DOI
  19. Holden, 1969, Laboratory changes with chlordiazepoxide and thioridazine, alone and combined, Canadian Psychiatric Association Journal, 14, 299, 10.1177/070674376901400311 · doi:10.1177/070674376901400311
  20. Holden, 1968, Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia, Comprehensive Psychiatry, 9, 633, 10.1016/S0010-440X(68)80059-8 · DOI
  21. Kurland, 1966, Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings, Journal of New Drugs, 6, 80, 10.1177/009127006600600203 · DOI
  22. Michaux, 1966, Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients, Current Therapeutic Research Clininical and Experimental, 8, 117
  23. Kutcher, 1989, Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study, Journal of Clinical Psychopharmacology, 9, 403, 10.1097/00004714-198912000-00003 · DOI
  24. Lerner, 1979, Acute high-dose parenteral haloperidol treatment of psychosis, American Journal of Psychiatry, 136, 1061, 10.1176/ajp.136.8.1061 · DOI
  25. Lingjaerde, 1979, Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients - A double-blind clinical trial, Current Therapeutic Research, 26, 505
  26. Lingjaerde, 1982, Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. A multicentre double-blind, cross-over study, Acta Psychiatrica Scandinavia, 65, 339, 10.1111/j.1600-0447.1982.tb00855.x · doi:10.1111/j.1600-0447.1982.tb00855.x
  27. Ma, 2006, The control study of injection of clonazepam into tinggong for auditory hallucination of schizophrenia, Journal of Clinical Psychosomatic Diseases, 12, 338
  28. Marneros, 1979, Anxiolytische Zusatzbehandlung bei den affektbetonten Schizophrenien. Ein Doppelblindversuch, Therapiewoche 29, 44, 7533
  29. Merlis, 1962, A double-blind comparison of diazepam, chlordiazepoxide and chlorpromazine in psychotic patients, Journal of Neuropsychiatry, 3, 133
  30. Minervini, 1990, Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients, Pharmacopsychiatry, 23, 102, 10.1055/s-2007-1014491 · doi:10.1055/s-2007-1014491
  31. Morphy, 1986, A double-blind comparison of alprazolam and placebo in the treatment of anxious schizophrenic outpatients, Current Therapeutic Research, 40, 551
  32. Nestoros, 1982, Diazepam in high doses is effective in schizophrenia, Progress in Neuro- Psychopharmacolgy and Biological Psychiatry, 6, 513, 10.1016/S0278-5846(82)80141-3 · DOI
  33. Nishikawa, 1982, Prophylactic effect of neuroleptics in symptom-free schizophrenics, Psychopharmacology, 77, 301, 10.1007/BF00432759 · DOI
  34. Pujalte, 1994, A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia, Clinical Neuropharmacology, 17, 236, 10.1097/00002826-199406000-00003 · DOI
  35. Stevens, 1992, Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis, Pharmacopsychiatry, 25, 273, 10.1055/s-2007-1014421 · doi:10.1055/s-2007-1014421
  36. TREC Collaborative Group, 2003, Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethiazine, BMJ, 327, 708, 10.1136/bmj.327.7417.708 · DOI · Paper page
  37. Wang, 2000, the control study of injection of clonazepam into t´ingkung for refractory auditory hallucination of schizophrenics, Journal of Clinical Psychosomatic Diseases, 6, 143
  38. Wang, 2003, An efficacy study of risperidone combined with clonazepam injection in the treatment of paranoid schizophrenia, Journal of Clinical Psychologic Medicine, 13, 217
  39. Wyant, 1990, The use of midazolam in acutely agitated psychiatric patients, Psychopharmacology Bulletin, 26, 126
  40. Xuan, 2007, Clinical observation on the effect of risperidone combined with BZD on schizophrenia, China Tropical Medicine, 7, 244
  41. Adler, 1985, Efficacy of propranolol in neuroleptic-induced akathisia, Journal of Clinical Psychopharmacology, 5, 164, 10.1097/00004714-198506000-00009 · DOI
  42. Alexander, 2004, Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine, British Journal of Psychiatry, 186, 63, 10.1192/bjp.185.1.63 · DOI · Paper page
  43. Altamura, 1987, Clonazepam/haloperidol combination therapy in schizophrenia: A double blind study, Acta Psychiatrica Scandinavica, 76, 702, 10.1111/j.1600-0447.1987.tb02942.x · DOI
  44. Ananth, 1979, Doxepin in geriatric patients, Current Therapeutic Research, 25, 133
  45. Bao, 2007, The effectiveness of aripiprazole combined with clonazepam treated with agitation in schizophrenia, Medical Journal of Chinese People's Health, 5, ni
  46. Bienek, 1998, A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation, Pharmacotherapy, 18, 57, 10.1002/j.1875-9114.1998.tb03827.x · DOI
  47. Bobruff, 1981, Clonazepam and phenobarbital in tardive dyskinesia, American Journal of Psychiatry, 138, 189, 10.1176/ajp.138.2.189 · doi:10.1176/ajp.138.2.189
  48. Cohen, 1987, Adjunctive benzodiazepines in acute schizophrenia, Neuropsychobiology, 18, 9, 10.1159/000118386 · doi:10.1159/000118386
  49. Crosse, 1974, Clinical trials of sulpiride (1403 R.D.--Dogmatil): Its advantages prescribed alone or in combination, Psychologie Médicale, 6, 1623
  50. Csernansky, 1988, Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative symptoms, Archive of General Psychiatry, 45, 655, 10.1001/archpsyc.1988.01800310063008 · doi:10.1001/archpsyc.1988.01800310063008
  51. Csernansky, 1988, The effect of benzodiazepines on tardive dyskinesia symptoms, Journal of Clinical Psychopharmacology, 8, 154, 10.1097/00004714-198804000-00028 · doi:10.1097/00004714-198804000-00028
  52. Dubin, 1988, Rapid tranquilization: antipsychotics or benzodiazepines, Journal of Clinical Psychiatry, 49, 5
  53. Ge, 2004, A comparative study of risperidone combining clonazepam and haloperidol in the treatment of patients with schizophrenia, Shandong Archives of Psychiatry, 17, 134
  54. Greenfeld, 1987, Treatment of catatonia with low-dose lorazepam, American Journal of Psychiatry, 144, 1224, 10.1176/ajp.144.9.1224 · DOI
  55. Haas, 1982, Analgesic and euphoric effects of high dose diazepam in schizophrenia, Neuropsychobiology, 8, 123, 10.1159/000117886 · doi:10.1159/000117886
  56. Hanus, 1973, A new tranquilizer: lorazepam (158 cases), Semaine des Hopitaux (Therapeutique), 49, 349
  57. Hartelius, 1978, A controlled long-term study of flunitrazepam, nitrazepam and placebo, with special regard to withdrawal effects, Acta Psychiatrica Scandinavica, 58, 1, 10.1111/j.1600-0447.1978.tb06915.x · DOI
  58. Harvey, 2004, Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia, Journal of Clinical Pharmacology, 44, 1173, 10.1177/0091270004267807 · DOI
  59. He, 2007, [Title only available in Chinese characters], Modern Medicine and Health, 23, 527
  60. Hekimian, 1967, A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients, Diseases of Nervous System, 28, 675
  61. Hesso, 1975, Clinical trial with a new substance (PLP 100-127) in order to asses therapeutic efficacy and dependence creating properties, Behavioral Neuropsychiatry, 7, 13
  62. Horiguchi, 1992, Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study, Japanese Journal of Psychiatry and Neurology, 46, 733
  63. Hovens, 2005, Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study, Journal of Psychopharmacology, 19, 51, 10.1177/0269881105048897 · DOI
  64. Hu, 2004, Investigation of administering BZD medicament in outpatients with psychosis, Heath Psychology Journal, 12, 43
  65. Itil, 1972, SCH-12,041, a new anti-anxiety agent (quantitative pharmaco-electroencephalography and clinical trials), Behavioral Neuropsychiatry, 4, 15
  66. Jibiki, 1994, Beneficial effect of high-dose clotiazepam on intractable auditory hallucinations in chronic schizophrenic patients. An open trial, European Journal of Clinical Pharmacology, 46, 367, 10.1007/BF00194407 · doi:10.1007/bf00194407
  67. Jimerson, 1982, Diazepam in schizophrenia: a preliminary double-blind trial, American Journal of Psychiatry, 139, 489, 10.1176/ajp.139.4.489 · doi:10.1176/ajp.139.4.489
  68. Jungkunz, 1984, Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in schizophrenic patients. A double blind trial, Pharmacopsychiatry, 17, 76, 10.1055/s-2007-1017412 · doi:10.1055/s-2007-1017412
  69. Kang, 2006, Clinical study on efficacy of quetiapine combined with clonazepam treated with acute agitation in schizophrenia patients, Linchuang Jingshen Yixue Zazhi, 16, 221
  70. Karson, 1982, Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial, American Journal of Psychiatry, 139, 1627, 10.1176/ajp.139.12.1627 · DOI
  71. Kellner, 1975, Anxiety in schizophrenia. The responses to chlordiazepoxide in an intensive design study, Archives of General Psychiatry, 32, 1246, 10.1001/archpsyc.1975.01760280044004 · DOI
  72. Knott, 2006, Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department, Annals of Emergency Medicine, 47, 61, 10.1016/j.annemergmed.2005.07.003 · DOI
  73. Li, 2004, [Title only available in Chinese characters], Chinese Journal of Clinical Medicine, 3, 33
  74. Li, 2007, Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the treatment of schizophrenia with excitement and agitation, Shanghai Archives of Psychiatry, 19, 150
  75. Maar, 1983, Comparison of two benzodiazepines in general psychosomatic disturbances, Therapiewoche, 33, 1251
  76. Mei, 2006, Clinical observation on acute excitation of schizophrenia treated with QIWEI combined with clonazepam, Chinese Nursing Research, 20, 1176
  77. Monroe, 1967, Chlordiazepoxide in the treatment of patients with "activated EEG's", Diseases of Nervous System, 28, 390
  78. Nestros, 1983, High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients, Psychopharmacology, 81, 42, 10.1007/BF00439272 · DOI
  79. Nobay, 2004, A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients, Academic Emergency Medicine, 11, 744
  80. Pato, 1989, Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia, Psychopharmacology Bulletin, 25, 263
  81. Pecknold, 1993, Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia, The Journal of Psychiatric Neurosciences, 18, 82
  82. Qin, 2005, A comparative study of risperidone combining alprazolam and clozapine in the treatment of patients with schizophrenia, Heath Psychology Journal, 13, 444
  83. Remington, 1993, Placebo response in refractory tardive akathisia, Canadian Journal of Psychiatry, 38, 248, 10.1177/070674379303800404 · DOI
  84. Richards, 1998, Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol, The Journal of Emergency Medicine, 16, 567, 10.1016/S0736-4679(98)00045-6 · DOI · Paper page
  85. Ruskin, 1979, Benzodiazepind in chronic schizophrenia, Biological Psychiatry, 14, 557
  86. Salam, 1988, Lorazepam treatment of psychogenic catatonia: an update, Journal of Clinical Psychiatry, 49, 16
  87. Saletu, 1971, Effect of minor and major tranquilizers on somatosensory evoked potentials, Psychopharmacologia, 24, 349
  88. Shafti, 2004, Rehabilitation of schizophrenia: adjunctive therapy of negative symptoms, Iranian Rehabilitation Journal, 2, ni
  89. Shafti, 2005, Drug-specific responsiveness of negative symptoms, International Journal of Psychosocial Rehabilitation, 10, 43
  90. Soldatos, 1986, Behavioral side effects of triazolam in psychiatric inpatients: report of five cases, Drug Intelligence and Clinical Pharmacy, 20, 294, 10.1177/106002808602000418 · DOI
  91. Sterlin, 1971, Doxepin as adjuvant medication in the treatment of chronic schizophrenic patients: a comparative study, Current Therapy Research Clinical and Experimental, 13, 50
  92. Stonehill, 1966, A comparative study with Benzodiazepines in chronic psychotic patients, Diseases of the Nervous System, 27, 411
  93. Tang, 2007, A clinical study of risperidone oral solution combined with clonazepam injection in the treatment of acute excitement phase schizophrenia patient, Shanghai Archives of Psychiatry, 19, 153
  94. Alexander, 2004, Rapid tranquilisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethiazine, British Journal of Psychiatry, 185, 63, 10.1192/bjp.185.1.63 · DOI · Paper page
  95. Wang, 2004, A controlled study of compound diazepam in adjunctive treatment for schizophrenia, Journal of Binzhou Medical College, 27, 111
  96. Wang, 2004, A multicenter study of risperidone treatment for acute agitation in patients with schizophrenia, Chinese Journal of Psychiatry, 37, 88
  97. Wang, 2005, Treatment of 80 cases of schizophrenia manifesting acute erethitic symptoms with quetiapine combined with clonazepam, Herald of Medicine, 24, 687
  98. Wang, 1995, Clinical controlled study of perphenazine combined with alprazolam in treatment of negative symptoms, Chinese Journal of Pharmaco Epidemiology, 4, 137
  99. Weber, 1983, Diazepam in tardive dyskinesia, Drug Intelligence and Clinical Pharmacy, 17, 523, 10.1177/106002808301700705 · doi:10.1177/106002808301700705
  100. Weckowicz, 1960, Clinical trial of RO 5-0690 and chlorpromazine on disturbed chronic schizophrenic patients, Diseases of the Nervous System, 21, 527
  101. Wolkowitz, 1986, Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia, American Journal of Psychiatry, 143, 85, 10.1176/ajp.143.1.85 · DOI
  102. Wolkowitz, 1988, Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients - Preliminary results, Archives of General Psychiatry, 45, 664, 10.1001/archpsyc.1988.01800310072009 · DOI
  103. Wu, 2006, [Title only available in Chinese characters], Journal of Qiqihar Medical College, 27, 536
  104. Yang, 2003, A randomly controlled comparison of risperidone added with intramuscular clonazepam in the treatment of excitement of schizophrenia, Shanghai Archives of Psychiatry, 15, 98
  105. Yu, 2006, [Title only available in Chinese characters], Nervous Diseases and Mental Hygiene, 6, 129
  106. Zhang, 2007, Study of olanzapine combined with clonazepam in treatment of schizophrenia with acute psychomotor excitation, Linchuang Jingshen Yixue Zazhi, 17, 239
  107. Zhang, 2008, [Title only available in Chinese characters], Shandong Archives of Psychiatry, 21, 59
  108. Davis, 2008, The emergency treatment of acutely agitated psychotic schizophrenia patient, International Journal of Neuropsychopharmacology, 11, 163
  109. Maculans, 1964, Comparison of diazepam, chlorprothixine and chlorpromazine in chronic schizophrenic patients, Diseases of the Nervous System, 25, 164
  110. Salzman, 1991, Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior, Journal of Clinical Psychiatry, 52, 177
  111. Ungvari, 1999, Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study, Psychopharmacology, 142, 393, 10.1007/s002130050904 · DOI · Paper page
  112. Adams, 2011, Cochrane Schizophrenia Group
  113. Andreasen, 1989, Scale for the assessment of negative symptoms, British Journal of Psychiatry, 155, 53, 10.1192/S0007125000291496 · DOI · Paper page
  114. Benkert, 2011, Kompendium der Psychiatrischen Pharmakotherapie, 10.1007/978-3-642-13044-1 · DOI · Paper page
  115. Bland, 1997, Statistics notes. Trials randomised in clusters, BMJ, 315, 600, 10.1136/bmj.315.7108.600 · DOI · Paper page
  116. Boissel, 1999, The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use, Therapie, 54, 405
  117. Carpenter, 1994, Schizophrenia, New England Journal of Medicine, 330, 681, 10.1056/NEJM199403103301006 · DOI · Paper page
  118. Cheine, 2001, Beta-blocker supplementation of standard drug treatment for schizophrenia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD000234 · DOI
  119. Christison, 1991, When symptoms persist: choosing among alternative somatic treatments for schizophrenia, Schizophrenia Bulletin, 17, 217, 10.1093/schbul/17.2.217 · DOI · Paper page
  120. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  121. Essali, 2009, Clozapine versus typical neuroleptic medication for schizophrenia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD000059.pub2 · DOI · Paper page
  122. Falkai, 2005, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia, World Journal of Biological Psychiatry, 6, 132, 10.1080/15622970510030090 · DOI · Paper page
  123. Falkai, 2005, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia, World Journal of Biological Psychiatry, 7, 5, 10.1080/15622970500483177 · DOI · Paper page
  124. Gillies, 2005, Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003079.pub2 · DOI
  125. Gulliford, 1999, Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994, American Journal of Epidemiology, 149, 876, 10.1093/oxfordjournals.aje.a009904 · DOI · Paper page
  126. Guy, 1976, ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale)
  127. Honigfeld, 1965, The nurses' observation scale for inpatient evaluation. A new scale for measuring improvement in chronic schizophrenia, Journal of Clinical Psychology, 21, 65, 10.1002/1097-4679(196501)21:1<65::AID-JCLP2270210122>3.0.CO;2-I · DOI · Paper page
  128. Kay, 1986, Positive and negative syndrome scale (PANSS) manual
  129. Lehman, 2004, Practice guideline for the treatment of patients with schizophrenia, second edition, American Journal of Psychiatry, 161, 1
  130. Leucht, 2005, What does the PANSS mean?, Schizophrenia Research, 79, 231, 10.1016/j.schres.2005.04.008 · DOI · Paper page
  131. Leucht, 2005, Clinical implications of Brief Psychiatric Rating Scale scores, British Journal of Psychiatry, 187, 366, 10.1192/bjp.187.4.366 · DOI · Paper page
  132. Leucht, 2006, Linking the PANSS, BPRS, and CGI: clinical implications, Neuropsychopharmacology, 31, 2318, 10.1038/sj.npp.1301147 · DOI · Paper page
  133. Leucht, 2003, Lithium for schizophrenia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003834.pub2 · DOI
  134. Leucht, 2011, Evidence-based pharmacotherapy of schizophrenia, International Journal of Neuropsychopharmacology, 14, 269, 10.1017/S1461145710001380 · DOI
  135. Lorr, 1962, Evidence of ten psychotic symptoms, Journal of Consulting Psychology, 26, 185, 10.1037/h0040653 · DOI
  136. Malamud, 1947, A revision of the psychiatric rating scale, American Journal of Psychiatry, 104, 231, 10.1176/ajp.104.4.231 · DOI
  137. Marvaha, 2004, Schizophrenia and employment ? a review, Social Psychiatry and Psychiatric Epidemiology, 39, 337, 10.1007/s00127-004-0762-4 · DOI · Paper page
  138. National Institute for Clinical Excellence (NICE), 2009, Core interventions in the treatment and management of schizophrenia in primary and secondary care (update)
  139. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008
  140. Schulz, 1995, Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA, 273, 408, 10.1001/jama.1995.03520290060030 · DOI
  141. Schwarz, 2008, Valproate for schizophrenia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004028.pub3 · DOI
  142. Simpson, 1970, A rating scale for extrapyramidal side effects, Acta Psychiatrica Scandinavica, 212, 11, 10.1111/j.1600-0447.1970.tb02066.x · DOI · Paper page
  143. Tharyan, 2005, Electroconvulsive therapy for schizophrenia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD000076.pub2 · DOI · Paper page
  144. Tsuang, 1978, Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality, Archives of General Psychiatry, 35, 153, 10.1001/archpsyc.1978.01770260031002 · DOI · Paper page
  145. Ukoumunne, 1999, Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review, Health Technology Assessment, 3, 1, 10.3310/hta3050 · DOI · Paper page
  146. Wahlbeck, 2001, Drop-out rates in randomised antipsychotic drug trials, Psychopharmacology, 155, 230, 10.1007/s002130100711 · DOI · Paper page
  147. World Health Organization, 2001, World Health Report 2001. Mental health - new understanding, new hope
  148. Xia, 2009, Loss to outcomes stakeholder survey: the LOSS study, Psychiatric Bulletin, 33, 254, 10.1192/pb.bp.108.021949 · doi:10.1192/pb.bp.108.021949
  149. Volz, 2007, Benzodiazepines for schizophrenia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006391 · DOI

Cited by

Metadata

Authors
Dold, M., Li, C., Tardy, M., Khorsand, V., Gillies, D., & Leucht, S.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2012-11-14
Volume
2012
Issue
11
Pages
CD006391-CD006391
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2110876125
Cited by
169
References
18
FWCI
8.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.